Furthermore, feladilimab enhanced the production of IFNγ, IL17, IL10, and TNFα by TCR-activated healthy donor and cancer patient PBMC (Fig. 2H; Supplementary Figs. S5C, S5D, and S6D). Here, IL17A is linked to cancer.